title: The expression of metallothionein (MT) and proliferation intensity in ovarian cancers treated with cisplatin and paclitaxel.
abstract: Metallothioneins (MT) represent low molecular weight proteins that are supposed to fulfil several functions. They participate in the cell cycle, protect cells from oxidative stress, control levels of heavy metals and participate in multidrug resistance processes, particularly in cases of alkylating drugs. The present study aimed at evaluation of proliferation intensity (Ki67, PCNA) in ovarian cancers treated using cisplatin and paclitaxel, as related to expression of MT. The experiments were performed on samples originating from 10 patients operated on due to ovarian cancer. The material originated from the first operations or second-look operations. All the patients were treated with cisplatin and paclitaxel. Immunocytochemical reactions using antibodies to MT, Ki67 and PCNA were performed in paraffin sections originating from the cases studied. Statistical analysis was performed using Statistica software. The studies demonstrated no relation between expression of MT on the one hand and intensity of proliferation before or after chemotherapy on the other hand (gamma correlation, p > 0.05). The results indicate that expression of MT is not related to resistance to treatment using cisplatin and paclitaxel.
authors.affiliation: Department of Histology and Embryology, University of Medical Sciences, Poznań, Poland. pawel.surowiak@interia.pl
authors.forename: Paweł
authors.initials: P
authors.lastname: Surowiak
authors.forename: Irina
authors.initials: I
authors.lastname: Kaplenko
authors.forename: Marek
authors.initials: M
authors.lastname: Spaczyński
authors.forename: Maciej
authors.initials: M
authors.lastname: Zabel
mesh_terms: D000230:Adenocarcinoma / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000378:metabolism; D002452:Cell Count; D002455:Cell Division; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000378:metabolism; D008668:Metallothionein / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000473:pathology / Q000628:therapy; D017239:Paclitaxel / Q000008:administration & dosage; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D019394:Ki-67 Antigen; D018809:Proliferating Cell Nuclear Antigen; D008668:Metallothionein; D017239:Paclitaxel; D002945:Cisplatin